These findings suggest that DWac can ameliorate MRC by increasing M2 macrophage polarization and correcting the disturbance of gut microbiota and Th1/Th17/Treg; therefore, we suggest DWac may become a promising drug for patients with mesalazine-sensitive and mesalazine-resistant colitis. Here, CD200 is linked to colitis.